Strategic report Governance & remuneration Financial statements Investor information Annual report on remuneration continued Remuneration governance The Remuneration Committee Adviser to the Committee Remuneration Committee Chairman Urs Rohner joined the Board The Committee has access to external advice as required.
The and was appointed to the Committee on 1 January 2015.
He was Committee carried out a formal review of the independent advisers appointed Committee Chairman with effect from 8 May 2015, to the Committee in 2013.
As a result of this review, the Committee following the retirement of Tom fide Swaan as Committee Chairman reappointed Deloitte LLP to provide it with independent advice on and Non-Executive Director on 7 May 2015. executive remuneration.
The Committee Chairman agrees the protocols under which Deloitte provides advice and the Committee Role of the Committee is satisfied that the advice they have received from Deloitte has The role of the Committee is to set the companys remuneration been objective and independent.
policy so that GSK is able to recruit, retain and motivate its executives.
The remuneration policy is regularly reviewed to Deloitte is a member of the Remuneration Consultants Group and, ensure that it is consistent with the companys scale and scope as such, voluntarily operates under the code of conduct in relation of operations, supports the business strategy and growth plans to executive remuneration consulting in the UK.
The code of conduct and helps drive the creation of shareholder value.
Terms of reference Deloitte provided independent commentary on matters under The Committees full terms of reference are available on the consideration by the Committee and updates on market practice companys website.
The terms of reference, which are reviewed and legislative requirements.
Deloittes fees for advice provided to at least annually, were last revised in January 2016 to reect best the Committee in 2015 were 138,130.
Fees were charged on a practice and corporate governance developments.
Deloitte LLP also provided other consulting, tax and assurance services to GSK during the year.
However, the Governance Committee is satisfied that this does not compromise the The Board considers all of the members of the Committee to be independence of the advice they have received from Deloitte.
independent Non-Executive Directors in accordance with the UK Corporate Governance Code.
Willis Towers Watson provided additional market data to the Committee.
The Committee met six times in scheduled meetings during 2015, Shareholder votes on remuneration matters with each member attending as follows: Votes 2015 Total votes Total votes Total votes withheld AGM cast billion for % against % million Committee Attendance at full Members member since meetings during 2015 Remuneration report 3.5 98.03 1.97 205 Urs Rohner 1 January 2015 6 6 Votes Chairman from 7 May 2015 2014 Total votes Total votes Total votes withheld Vindi Banga 1 January 2016 0 0 AGM cast billion for % against % million Dr Stephanie Burns 1 May 2013 6 6 Remuneration report 3.4 98.5 1.5 171 Judy Lewent 1 January 2013 6 6 Remuneration policy 3.5 97.4 2.6 100 Sir Deryck Maughan 1 July 2012 5 6 Consideration of shareholder views Hans Wijers 10 October 2013 5 6 The Committee engages in regular dialogue with shareholders and holds annual meetings with GSKs largest investors to discuss and Sir Christopher Gent 1 January 2007 3 3 take feedback on its remuneration policy and governance matters.
Tom fide Swaan 20 May 2009 3 3 Chairman to 7 May 2015 The annual meetings were held in November 2015, at which Urs Rohner, Committee Chairman, shared updates on remuneration Sir Christopher Gent and Tom fide Swaan retired from the Board on 7 May 2015. matters in the last 12 months and proposals for 2016 onwards.
In addition to the six scheduled meetings, the Committee met on In particular this covered proposed enhanced annual bonus a quorate basis on three occasions to approve the formal grant of disclosures for inclusion in the 2015 Annual Report.
In addition, long-term incentive awards to employees below the CET, and investors initial views were sought on the future development of address other LTI administrative matters.
the approved Remuneration Policy in advance of the anticipated submission by the company of a binding shareholder resolution to Committee meetings usually include a closed session, during approve a new Remuneration Policy at the 2017 AGM.
which only members of the Committee are present.
Other individuals may also be invited to attend Committee meetings Committee evaluation during the year.
Executives and other Committee attendees The Committees annual evaluation was internally facilitated by are not involved in any decisions, and are not present at any the Company Secretary, and supplemented by a questionnaire discussions regarding their own remuneration.
circulated to Committee members on behalf of the Committee Chairman.
It was concluded that the Committee continued to The Company Secretary is Secretary to the Committee and operate effectively.
In terms of enhancements to the Committees attends all meetings.
Other attendees at Committee include: deliberations it was agreed that the Committee would focus its attention during 2016 on reviewing the companys Remuneration Regular Attends as Policy.
Attendee attendee required CEO CFO Head of Human Resources Head of Reward Committee Adviser Deloitte LLP 116 GSK Annual Report 2015 Strategic report Governance & remuneration Financial statements Investor information Remuneration governance continued Principal activities and matters addressed during 2015 Remuneration Governance and Items specic to: Month Overall Annual bonus and LTIs other matters Approve CET salary increase Review and approve R&D Annual bonus Review draft 2014 Remuneration report January recommendations target metric Review shareholder feedback from Review and approve executives 2014 annual investor meetings bonuses Review Committee external evaluation Set CEO 2015 bonus objectives report Update on Deferred Annual Bonus Plan Rules Update on LTI performance for 2012 LTI awards 2012-2014 February Receive update on remuneration Review LTI performance outcomes and Review 2014 Remuneration report related implications of the Novartis approve vesting of 2012 LTI awards transaction 2012-2014 for CET and below CET Review and approve 2015-2017 LTI grants for CET and below Grant interim Share Value Plan awards below CET Remuneration environment update Update on Performance Share Plan for Update on remuneration considerations March employees below CET for 2015 Grant awards to certain eligible former Novartis employees Review of CEO and CFO pay Approve adjusted free cash ow target Review AGM and remuneration report July competitiveness for 2015 awards following completion of feedback, the external remuneration the Novartis transaction environment and performance target Review of remuneration benchmark disclosures for incentive plans comparator groups Approve Committee evaluation process Review Chairman fees Environmental update August Grant interim and main Share Value Plan awards below CET Consider remuneration Update on LTI vesting for 2013 awards Update on remuneration report October report disclosures for 2015 2013-2015 disclosures Update on CEO, CFO Review adjustment principles for LTI Preparation for annual investor and CET remuneration competitiveness measures in respect of the Novartis meetings transaction Draft plan for review of remuneration policy for 2017 AGM November Annual meeting with investors Annual CET benchmarking and Grant awards to certain eligible former Review Investment Association December competitiveness review Novartis employees Principles of Remuneration Approve Executive Director salary Update on remuneration report increases for 2016 disclosures Review shareholder feedback from annual investor meetings GSK Annual Report 2015 117
